Associated Papers
Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances.
Deng F et al.
Cancers, 2026
Autoregulation of the MET receptor tyrosine kinase by its intracellular juxtamembrane domain.
Linossi EM et al.
The Biochemical Journal, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.
Hu J et al.
Molecular Oncology, 2025
Evolving roles of MET as a therapeutic target in NSCLC and beyond.
Lee JB et al.
Nature Reviews. Clinical Oncology, 2025
Complementary modes of resistance to EGFR TKI in lung adenocarcinoma through MAPK activation and cellular plasticity.
Zatzman M et al.
Biorxiv : the Preprint Server for Biology, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam GO et al.
Elife, 2025
Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.
Lin H et al.
Communications Biology, 2025
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam GO et al.
Biorxiv : the Preprint Server for Biology, 2024
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
Marks JA et al.
Lung Cancer (amsterdam, Netherlands), 2024
Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy.
Bumpers QA et al.
Journal of Medicinal Chemistry, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
Recording and classifying MET receptor mutations in cancers.
Guérin C et al.
Elife, 2024
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
Patil T et al.
Jto Clinical and Research Reports, 2024
Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding.
Grädler U et al.
The Journal of Biological Chemistry, 2023
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Spitaleri G et al.
Cancers, 2023
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.
Jóri B et al.
Current Oncology (toronto, Ont.), 2023
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer.
Zhou J et al.
Signal Transduction and Targeted Therapy, 2023
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
An In silico Approach towards Finding the Cancer-Causing Mutations in Human MET Gene.
Laskar FS et al.
International Journal of Genomics, 2023
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report.
Choi W et al.
Translational Lung Cancer Research, 2022
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T et al.
Journal of Hematology & Oncology, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Bahcall M et al.
Molecular Cancer Therapeutics, 2022
Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease.
Blaquier JB et al.
Drugs in Context, 2022
Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients.
Shang Y et al.
Frontiers in Oncology, 2022
Dramatic response to osimertinib combined with crizotinib in EGFR T790 M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer: A case report.
Li D et al.
Medicine, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Lin JJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Lee M et al.
Expert Opinion on Therapeutic Targets, 2021
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations.
Santarpia M et al.
Translational Lung Cancer Research, 2021
Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
Lee JK et al.
Jco Precision Oncology, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
[Chinese Expert Consensus on Next Generation Sequencing Diagnosis for Non-small Cell Lung Cancer (2020 Edition)].
Unknown Author
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2020